ArticleMedical microbiology and immunology2025
Pseudomonas fragi or not? Beyond MALDI-TOF in the frontier of Pseudomonas diversity.
Article in Medical microbiology and immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Advanced platforms, such as whole genome sequencing (WGS), should be employed to enhance and refine microbial identification compared to phenotypic methods, including miniaturized biochemical tests and MALDI-TOF. The application of WGS has led to the reclassification of clinical bacterial pathogens previously misidentified by phenotypic techniques. In this study, eight clinical isolates initially identified as Pseudomonas fragi by VITEK MS were subjected to WGS and bioinformatics analysis. The results revealed one strain as Pseudomonas lundensis, while average nucleotide identity and phylogenetic reconstruction suggested that the remaining seven strains represent novel species within the Pseudomonas fluorescens superclade. The strains harbored four antimicrobial resistance genes conferring resistance to β-lactams, fluoroquinolones, phenicols, and tetracyclines, yet in vitro assays indicated susceptibility to carbapenems and intermediate susceptibility to colistin. Additionally, the strains possessed virulence factor genes associated with alginate biosynthesis, flagellar formation, pilus assembly, and iron uptake, with Type III Secretion System (T3SS)-related genes detected only in P. lundensis. Notably, the isolated Pseudomonas spp., exhibited multiple haplotypes, a closely related pan-genome, and similar phenotypic characteristics. These findings underscore the necessity of integrating multiple approaches, including molecular methods such as 16S rRNA gene amplification, sanger sequencing, and WGS, alongside traditional phenotypic techniques, to improve the accuracy of microbial identification in clinical settings.
Indexed as
Identifiers
41051628What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.